

SUPPLEMENTAL MATERIAL

Table S1 PK parameters used for CQ modelling in human plasma and lung.

Parameter	Value used in Simulation	Source
k_a (h^{-1})	1	Karunajeewa et al. (1)
CL/F ($\text{L}/\text{h}/\text{kg}$)	28.2	
V_c/F (L/kg)	2702	
V_p/F (L/kg)	3781	
Q/F ($\text{L}/\text{h}/\text{kg}$)	20	
$Q_{\text{lung_in}}$ (L/h)	0.394	
$Q_{\text{lung_out}}$ (L/h)	$1.84 \cdot 10^{-3}$	From rat lung model
Apparent Lung Volume (L)	0.083	From rat lung model Calculated: $\left(\frac{V_{\text{lung}}[\text{RAT}]}{V_{\text{plasma}}[\text{RAT}]} \right) \cdot V_{\text{plasma}}[\text{HUMAN}]$

Table S2 Rat PK parameters estimated from data reported in Adelusi et al. 1988

Parameter	Value estimate	% RSE
k_a (h^{-1})	10 [fixed]	-
CL/F ($\text{L}/\text{h}/\text{kg}$)	1.99	10.7%
V_c/F (L/kg)	68.3	5.01%
V_p/F (L/kg)	44.6	39.7%
Q/F ($\text{L}/\text{h}/\text{kg}$)	2.99	33.2%
$Q_{\text{lung_in}}$ (L/h)	$9.9718 \cdot 10^{-3}$	23.7%
$Q_{\text{lung_out}}$ (L/h)	$4.66 \cdot 10^{-5}$	26.9%
Apparent Lung Volume (L)	0.0021 (fixed to physiological volume (2))	-

Table S3 Physicochemical properties and in vitro data of CQ experimentally derived or obtained from the literature

Parameter	Value (CQ)
Molecular weight	319.872 (3)
$\log P_{\text{o:w}}^a$	4.63
Protein binding	60% (4)
pK_a^b	10.1, 8.1 (5)
R^c	3.5 (6)
Plasma clearance	0.675 $\text{L}/\text{h}/\text{kg}$ (3)

a- $\log P_{\text{o:w}}$ – Partition coefficient between octanol and water.

b- pK_a – logarithmic value of the dissociation constant.

c- R – blood-to-plasma drug ratio.

Table S4 anti SARS-CoV-2 pharmacodynamic parameters used for CQ

Parameter	Value estimate	Reference
$E_{\text{max}} (\%)$	100	Wang et al. (7)
EC_{50} [μM]	1.13	
hill	1.23	

REFERENCES

- (1) Karunajeewa, H.A. *et al.* Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. *Antimicrob Agents Chemother* **54**, 1186-92 (2010).
- (2) Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. *Pharm Res* **10**, 1093-5 (1993).
- (3) DrugBank. *Chloroquine*. <<https://www.drugbank.ca/drugs/DB00608>> (2020). Accessed 14/04/2020 2020.
- (4) Ofori-Adjei, D., Ericsson, O., Lindstrom, B. & Sjoqvist, F. Protein binding of chloroquine enantiomers and desethylchloroquine. *British Journal of Clinical Pharmacology* **22**, 356-8 (1986).
- (5) Daniel, W.A., Bickel, M.H. & Honegger, U.E. The Contribution of Lysosomal Trapping in the Uptake of Desipramine and Chloroquine by Different Tissues. *Pharmacology & Toxicology* **77**, 402-6 (1995).
- (6) Charman, S.A. *et al.* An in vitro toolbox to accelerate anti-malarial drug discovery and development. *Malar J* **19**, 1 (2020).
- (7) Wang, M. *et al.* Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* **30**, 269-71 (2020).